Rintega (rindopepimut) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme (GBM) that test positive for the EGFR variant (EGFRvIII).
Peter J. Sciavolino, PhD
Advertisement
Articles by Peter J. Sciavolino, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ASCO 2026 That Patients Should Know
2
Pumitamig Shows 70% Response in Advanced Lung Cancer Regardless of PD-L1 Status
3
How a Teen Cancer Survivor and Her Best Friend Created an App to Help Patients Between Appointments
4
Iza-Bren Improves Survival in Metastatic Triple-Negative Breast Cancer
5